VENTANA MMR RxDx Panel
Ventana Medical Systems · Decision date Apr 22, 2021
What did the FDA approve?
FDA records P200019 as an original PMA application. The recorded decision is approval, dated Apr 22, 2021.
FDA approval order statement
Approval for the Ventana MMR RxDx Pavel as a CDx for identifying patients with endometrial cancer with dMMR status who may benefit from treatment with Jemperli.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Apr 22, 2021
Regulatory record facts
- Identifier
- P200019
- Regulatory pathway
- Premarket approval application
- Applicant
- Ventana Medical Systems
- Product code
- QNH
- Decision code
- APPR
- Decision date
- Apr 22, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.
- Applicant
- Ventana Medical Systems
- Product code
- QNH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200019 received
Application receipt date recorded by FDA.
P200019 · FDA decision
APPR
P200019/S014 · Related supplement
VENTANA MMR RxDx Panel
Timeline entries are records held by MedtechLedger for P200019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP200019/S014 | Ventana Medical Systems | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QNH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP210001/S016 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 8, 2026 | FDA |
MMR IHC Panel pharmDx (Dako Omnis)P250004/S001 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
| Agilent Technologies, Inc. | PMA approval | Aug 15, 2025 | FDA | |
VENTANA MMR RxDx PanelP210001 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA approval | Aug 17, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P200019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


